Amgen (NASDAQ:AMGN) Releases Quarterly Earnings Results, Beats Estimates By $0.74 EPS

Key Points

• Amgen reported earnings of $6.02 EPS for the quarter, exceeding analysts' estimates of $5.21 by $0.81.
• The company updated its FY 2025 guidance to $20.200-21.300 EPS while announcing a quarterly dividend of $2.38 per share, reflecting a 3.2% dividend yield.
• Amgen's stock decreased by 0.6% to $300.08, with a recent consensus rating of "Hold" and a target price of $307.27 from analysts.

Amgen (NASDAQ:AMGN - Get Free Report) released its quarterly earnings results on Tuesday. The medical research company reported $6.02 earnings per share for the quarter, topping analysts' consensus estimates of $5.28 by $0.74, Zacks reports. Amgen had a return on equity of 176.11% and a net margin of 17.39%. During the same period in the previous year, the business posted $4.97 earnings per share. The firm's revenue was up 9.4% on a year-over-year basis. Amgen updated its FY 2025 guidance to 20.200-21.300 EPS.

Amgen Trading Down 0.6%

Shares of AMGN traded down $1.86 during mid-day trading on Tuesday, reaching $300.08. The company had a trading volume of 2,661,831 shares, compared to its average volume of 2,904,146. Amgen has a fifty-two week low of $253.30 and a fifty-two week high of $339.17. The firm has a fifty day simple moving average of $292.64 and a 200-day simple moving average of $292.40. The stock has a market cap of $161.36 billion, a price-to-earnings ratio of 27.38, a price-to-earnings-growth ratio of 2.57 and a beta of 0.49. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.2%. Amgen's dividend payout ratio (DPR) is currently 86.86%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Bank of America lifted their price objective on Amgen from $252.00 to $261.00 and gave the stock an "underperform" rating in a report on Wednesday, July 23rd. Mizuho upped their target price on shares of Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a research report on Wednesday, May 7th. William Blair restated an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. Royal Bank Of Canada reduced their target price on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Finally, Guggenheim started coverage on Amgen in a research note on Tuesday, May 20th. They set a "neutral" rating and a $288.00 target price for the company. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $307.27.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president directly owned 8,162 shares in the company, valued at $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.69% of the company's stock.

Institutional Investors Weigh In On Amgen

An institutional investor recently raised its position in Amgen stock. Brighton Jones LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 23.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 27,468 shares of the medical research company's stock after purchasing an additional 5,226 shares during the quarter. Brighton Jones LLC's holdings in Amgen were worth $7,159,000 as of its most recent filing with the SEC. Institutional investors own 76.50% of the company's stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.